Immuron Limited (IMRN): Price and Financial Metrics


Immuron Limited (IMRN): $4.85

0.02 (+0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IMRN POWR Grades


  • IMRN scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.94% of US stocks.
  • The strongest trend for IMRN is in Stability, which has been heading up over the past 156 days.
  • IMRN ranks lowest in Growth; there it ranks in the 6th percentile.

IMRN Stock Summary

  • IMRN has a market capitalization of $21,616,397 -- more than approximately just 4.32% of US stocks.
  • The ratio of debt to operating expenses for Immuron Ltd is higher than it is for about only 0.48% of US stocks.
  • With a year-over-year growth in debt of -100%, Immuron Ltd's debt growth rate surpasses only 0% of about US stocks.
  • Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are HAPP, GIGM, SVVC, WAFU, and EDTK.
  • Visit IMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.immuron.com.au.

IMRN Stock Price Chart Interactive Chart >

Price chart for IMRN

IMRN Price/Volume Stats

Current price $4.85 52-week high $28.99
Prev. close $4.85 52-week low $1.92
Day low $4.68 Volume 14,400
Day high $4.93 Avg. volume 55,066
50-day MA $5.51 Dividend yield N/A
200-day MA $6.98 Market Cap 27.55M

Immuron Limited (IMRN) Company Bio


Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.


IMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream


Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about Immuron Ltd that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron (ASX:IMC) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | March 2, 2021

Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week. Details of the events are as follows: * H.C. Wainwright Virtual BioConnect Conference January 11 – 14, 2021: The company’s presentation will take place on Monday, January 11, 2021, at 6 a.m. US EST and will be available to all conference-registered institutional investors. A copy of the presentation will be available on Immuron’s website ...

Yahoo | January 11, 2021

Immuron SARS-CoV-2 Research Agreement with Monash University

Key Points * Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. * A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of th...

Yahoo | December 15, 2020

Immuron Receives AUD $358,280 R&D Tax Concession Refund

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year. This release has been authorised by the directors of Immuron Limited.COMPANY CONTACT: Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 [email protected]         About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceuti...

Yahoo | November 24, 2020

Immuron Shares Resume Trade Following Circuit Breaker To Upside; Stock Pulling Back From Session High, Still Up 30%

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …

Benzinga | November 11, 2020

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo 0.21%
3-mo -17.38%
6-mo -27.72%
1-year -43.87%
3-year -49.29%
5-year N/A
YTD -23.86%
2020 75.48%
2019 N/A
2018 0.00%
2017 N/A
2016 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8593 seconds.